Oragenics (NYSE:OGEN) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGENGet Free Report) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.

Oragenics Trading Up 18.9 %

NYSE:OGEN opened at $0.41 on Tuesday. The firm’s fifty day simple moving average is $0.34 and its 200 day simple moving average is $0.66. Oragenics has a twelve month low of $0.25 and a twelve month high of $6.42. The firm has a market capitalization of $5.01 million, a price-to-earnings ratio of -0.06 and a beta of 0.40.

Oragenics Company Profile

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Stories

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.